UK biotech venture capital hit a five-year high, with companies raising £2.05 billion in Q2 2026, driven in part by Isomorphic Labs’ £1.6 billion Series B. The BioIndustry Association said the surge helped rebalance funding across stages, with seed activity staying resilient while Series A and B+ rounds tracked higher. The report also highlighted a shift toward larger first rounds at earlier stages, a response to sustained fundraising friction and portfolio valuation resets after a slower funding window. Overall, the UK market is again acting as a liquidity engine for European biotech, which can translate into faster platform scaling and earlier clinic-entry planning for startups.